IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Lenvatinib oral chemotherapy is approved as a first-line treatment of patients with unresectable HCC. The efficacy and therapeutic duration of lenvatinib are limited by drug resistance, and the mechanism is...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yarong, Xu, Jun, Du, Qiang, Yan, Yihe, Geller, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988337/
https://www.ncbi.nlm.nih.gov/pubmed/33735820
http://dx.doi.org/10.1016/j.tranon.2021.101059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988337/
https://www.ncbi.nlm.nih.gov/pubmed/33735820
http://dx.doi.org/10.1016/j.tranon.2021.101059

Ejemplares similares